CervoMed Inc.
CRVO · XNASCIK 1053691fmd_1B60W7SB3YB8FHGRYCE12A5QC7制造业 · 医药制剂模板: 标准
覆盖范围: 2010年1月01日 至 2026年9月30日，共 65 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | – | – | 0 | 7 | 10 | 4 |
| 营业成本 | – | – | – | – | – | – | – | – | – | – |
| 毛利润 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 7 | 5 | 6 | 7 | 9 | 8 | 1 | 8 | 19 | 22 |
| 营业费用合计 | – | – | – | – | – | – | 3 | 15 | 28 | 32 |
| 营业利润 | (18) | (11) | (19) | (12) | (16) | (25) | (3) | (8) | (18) | (28) |
| 利息费用 | 0 | 0 | 0 | – | – | – | 0 | 0 | – | – |
| 利息及投资收益 | – | – | – | – | – | – | 0 | 0 | 2 | 1 |
| 其他营业外收入（支出） | – | – | – | – | – | – | (2) | 6 | 2 | 1 |
| 税前利润 | (18) | (2) | (19) | (11) | (16) | (25) | (16) | – | – | – |
| 所得税费用 | (0) | (1) | (0) | 0 | (2) | (0) | 0 | – | – | 0 |
| 持续经营净利润 | (18) | (1) | (18) | (12) | (14) | (24) | (16) | – | – | – |
| 净利润 | (18) | (1) | (18) | (12) | (14) | (24) | (6) | (2) | (16) | (27) |
| 归属于普通股股东的净利润 | (18) | (3) | (27) | (12) | (16) | (24) | – | – | – | – |